The use of recombinant factor VIIa in children with inherited platelet function disorders.
Almeida AM, Khair K, Hann I, Liesner R
Br J Haematol 2003;121(3):477-481.
Review by Aldouri M
The interaction between platelets and factor VII/VIIa.
Lau HKF
Transfus Apheresis Sci 2003;28(3):279-283.
Review by Aldouri M
Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device.
Potapov EV, Pasic M, Bauer M, Hetzer R
Ann Thorac Surg 2002;74(6):2182-2183.
Review by Aldouri M
Synthetic factor VIIa concentrate to treat coagulopathy and gastrointestinal bleeding in an infant with end-stage liver disease.
Tobias JD, Berkenbosch JW
Clin Pediatr (Phila) 2002;41(8):613-616.
Review by Aldouri M
Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta.
Kastrup M, von Heymann C, Hotz H, et al.
Ann Thorac Surg 2002;74(3):910-912.
Review by
The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.
Schreiber MA, Holcomb JB, Hedner U, Brundage SI, Macaitis JM, Hoots K
J Trauma 2002;53(2):252-257.
Review by Aldouri M
Massive blood transfusion in the elective surgical setting.
Nice overview, but inconsistency between recommendations in the figures and in the text. – V. Kretschmer
Application of recombinant activated factor VII during surgery for a giant skull base hemangiopericytoma to achieve safe hemostasis. Case report.
Gerlach R, Marquardt G, Wissing H, et al.
J Neurosurg 2002;96(5):946-948.
Review by
Epinephrine versus epinephrine plus fibrin glue injection in peptic ulcer bleeding: a prospective randomized trial.
A useful study (notwithstanding power) and review of current practices. – F. Regan and M. Contreras.
Survey of the use of whole blood in current blood transfusion practice.
MacLennan S, Murphy MF
Clin Lab Haematol 2001;23(6):391-396.
Review by
Use of recombinant factor VII in hepatology.
Romero Castro R, Barroso Relinque N, Caunedo Alvarez AC, et al.
Rev Esp Enferm Dig 2001;93(10):664-668.
Review by
Recombinant activated factor VII for adjunctive hemorrhage control in trauma.
Martinowitz U, Kenet G, Segal E, et al.
J Trauma 2001;51(3):431-438.
Review by M. Aldouri
Recombinant activated factor VII (RFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices.
This is a new open-label study, which showed efficacy of rFVIIa in normalising prothrombin time and effective control of bleeding esophageal varices in cirrhotic patients,... Read More
Development of an animal model for assessment of the hemostatic efficacy of fibrin sealant in vascular surgery.
Kheirabadi BS, Pearson R, Rudnicka K, et al.
J Surg Res 2001;100(1):84-92.
Review by R. K. Spence
High intensity focused ultrasound: A method of hemostasis.
This inovative work bears watching. Potential applications include minimally invasive, i.e., laparoscopic, approaches to control of traumatic liver injury. – R. K. Spence.
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659